RespireRx Pharmaceuticals Inc (CE) (RSPI) Share Price

The question is When ??

Good.....hit the door jack!

Why don't u just leave then 

We are not relying on it , just using it to see if it points us in a different direction or gives us a new link to other things of interest. Can I ask what you are contributing to the postings and if you are invested here at all.

LOL. Seems obvious.

Appearances are not everything.

Enough.. I don't want to see anymore posts here!

According to the companies shareholder letter 5 months ago, there were some hurdles to overcome and it was still a 2025 goal to get that phase 2 trial going and tap the DOD funds. It would be a material event once that trial begins.

Their key assets they are working towards clinical trials and eventually medicine can easily be found in their shareholder letter as well as the info on that makeshift website, EndeavourRx

KRM-ll-81 for pain with (NIH), epilepsy (grant funding with consultants)
CX-1739 for SCI (DoD funding) and ADHD (which they mention could use CX-717, but why not just use a superior compound CX1739)

These are company making progress and should be the primary focus moving forward. Once they land a funding and/or BP deal they are set up to then have a cascade of activity for the other platforms/indications supporting and extending the valuation reset. 10-20 pennies can then grow to .25-.50-.75 years down the road with success along multiple medical indication pathways.

"The trials are ongoing and the results are expected to be published in the future. "
In the future you say? They're not expected in the past?

The reliance on the second hand dd called AI that you guys have developed is laughable....or sad. Either way it's a bad idea.

AI Overview
Learn more
The results of the RespireRx Pharmaceuticals (RSPI) $1.8 million Department of Defense (DoD) grant for Phase 2A and 2B clinical trials testing CX1739 in spinal cord injured patients have not yet concluded. The trials are ongoing and the results are expected to be published in the future.
Here's a more detailed explanation:
The Grant:
RSPI received a $1.8 million DoD grant to fund a two-stage Phase 2A and 2B clinical study. The study is evaluating the safety and efficacy of CX1739, RespireRx's lead AMPAkine, in improving bladder function and motor activity in individuals with spinal cord injury (SCI).
Phase 2A and 2B:
The trial is divided into two phases. Phase 2A is a safety and efficacy study, and Phase 2B is a double-blind, placebo-controlled study.
Timeline:
The trial is ongoing and the results are expected to be published in the future.
Purpose:
The purpose of the study is to determine whether CX1739 can safely and effectively improve bladder function and motor activity in individuals with SCI.
Research Partner:
The study is being conducted by Shirley Ryan AbilityLab, a research and clinical center focused on rehabilitation.

They are as oppositely acute at business acumen as they are at applying science in their chosen areas, yes.

Maybe, but you can develop a professional perception of your company and its assets. It all goes hand in hand with refining the science and being thorough.

Professional perception leads to the development of high quality people resources, funding and partners and broadens the interest in investment and collaboration.

Good to hear. It will be interesting as to how they structure the assets and funding moving forward, exiting EM and which avenues they take immediately.

Tier 3/IND enabling for pain for almost 18 months now. What is the status/timeline of submitting IND and getting KRM-ll-81 into phase 1 trials.

And related, did they get the SBIR award for epilepsy IND enabling?

Then the amapkine platform has the phase 2 DOD funding sitting out there for a year now, waiting on what? And related, how will they approach ADHD and is that the source of the expected additional grant applications?

I guess also related to the ampakine platform. All the publication efforts are leading to what end? Are they looking to sell that platform like they had in the past? Or are they looking to add additional medical indications to pursue with CX-1739, like various cognitive disorders?

OSA program still viable?

The company internally valued themselves around 50 million according to one slide, but reality is any significant deal for the gabakine for phase 1 clinicals or additional grant funding will be multiples additive. Watching and waiting. Good luck to all.

Like a fine wine You can't hurry scientific inquiry in its being refined.

lol always has to be litteraly at the last moment. 2 seconds left on the game clock type of scenario lol

I think it is all coming together for them , I reached out and it appears that things are still on for late next week and or may go into the following week for news to be put out. GLTA

This all points out what appears to be an effort to expand potential utilizations of CX-1739. By all accounts I have read, CX-1739 appears to be superior to all other ampakines that Respire/Cortex previously worked with. That includes the less viable high impact ampakines as well as low impact ampakines cited in publications as well as their own CX-717.

Similar to how KRM-ll-81 has potentially best in class gabakine selectivity that may be applicable for pain, epilepsy, anxiety type indications... CX-1739 has potential utilization in SCI (DOD phase 2 funding) and certainly ADHD and now via these publications possible additional significant cognitive disorders.

Just a massive opportunity sitting right here with KRM-ll-81 and CX-1739. Both of these lead candidates have billion dollar potential. And why some reasonable speculation is that as clinicals initiate here this won't be sitting on the OTC long as this science will find major support funding and land on the NASDAQ at some point. Hoping whatever updates are forthcoming finally opens the flood gates and sets these assets firmly on the development path for many possible medical indications.

https://pubmed.ncbi.nlm.nih.gov/40245529/

AI Overview
Learn more
Yes, there are published papers on Ampalex-d10. Ampalex-d10, also known as CX-516-d10, is a deuterated version of the compound CX-516, which is a positive allosteric modulator of the AMPA receptor. It is used in research to study the pharmacology and effects of AMPA receptors and the compound's potential for therapeutic applications.
Here's a more detailed breakdown:
CX-516:
This is a compound that enhances the activity of AMPA receptors, which are essential for learning and memory.
Deuterated versions:
Deuteration (replacing hydrogen atoms with deuterium) is a common technique in research to study the metabolism and pharmacokinetic properties of drugs. Ampalex-d10 allows researchers to track the compound's fate in the body more accurately.
Ampalex-d10:
The deuterated version of CX-516, it is used to study the effects of AMPA receptor modulation on various processes, such as memory, learning, and cognitive function.
Published papers:
Several studies have been published on CX-516, including its effects on:
Memory enhancement in rats.
Cognitive deficits in schizophrenia.
Potential treatment for Alzheimer's disease and mild cognitive impairment (MCI).
Clinical trials:
Some clinical trials have investigated CX-516, including a placebo-controlled add-on trial in schizophrenia, according to the National Institutes of Health (NIH) (.gov).
BenchChem:
BenchChem offers Ampalex-d10 for research use, indicating its availability and continued use in scientific research.
In summary, Ampalex-d10 is a well-studied compound, and numerous papers have been published exploring its effects and potential applications, according to Selleckchem.com and other scientific resources.

https://www.medchemexpress.com/Ampalex.html?srsltid=AfmBOooqZUpx4B2oa5gcnVEZiVZpJDbAfGt8DRP5gqfAsA1RBiJrOfL1

https://pmc.ncbi.nlm.nih.gov/articles/PMC9585480/

AI Overview
Learn more
Yes, there are published research papers on Ampalex-d10, also known as deuterated Ampalex or deuterated CX516.
What is Ampalex-d10?
Ampalex-d10 is a deuterated analog of Ampalex (CX516), a positive allosteric modulator (PAM) of the AMPA receptor.
Deuteration involves replacing hydrogen atoms with deuterium, which can alter the metabolic stability and pharmacokinetic properties of a compound.
AMPA receptors are crucial for synaptic transmission and plasticity, and enhancing their activity is a potential therapeutic strategy for cognitive deficits.
Areas of Research:
Research papers on Ampalex-d10 and related compounds explore the following areas:
AMPA Receptor Modulation:
Studies investigate how Ampalex-d10 enhances the response of AMPA receptors to glutamate, leading to increased synaptic transmission.
Researchers examine the effects of AMPA receptor potentiation on synaptic plasticity and cognitive function.
Cognitive Enhancement:
Research explores the potential of Ampalex-d10 to improve cognitive function in animal models of various neurological disorders.
Studies assess its effects on memory, learning, and other cognitive processes.
Neuroprotection:
Some research indicates that Ampalex-d10 may possess neuroprotective properties, potentially protecting neurons from damage or stress.
Studies investigate its role in reducing neuronal apoptosis and promoting neuronal survival.
Therapeutic Potential:
Ampalex-d10 has been investigated for its potential therapeutic applications in conditions like Alzheimer's disease, schizophrenia, and attention deficit hyperactivity disorder (ADHD).
Research focuses on its ability to alleviate symptoms and improve cognitive deficits associated with these disorders.
Note:
It's important to remember that much of the research on Ampalex-d10 is preclinical (conducted in vitro or in animal models). More clinical trials are needed to determine its efficacy and safety in humans.

Google just the wording I guess

Deuterium in drug discovery: progress, opportunities and challenges

Rita Maria Concetta Di Martino, Brad D. Maxwell & Tracey Pirali

Nature Reviews Drug Discovery volume 22, pages562–584 (2023)

Abstract
Substitution of a hydrogen atom with its heavy isotope deuterium entails the addition of one neutron to a molecule. Despite being a subtle change, this structural modification, known as deuteration, may improve the pharmacokinetic and/or toxicity profile of drugs, potentially translating into improvements in efficacy and safety compared with the non-deuterated counterparts. Initially, efforts to exploit this potential primarily led to the development of deuterated analogues of marketed drugs through a ‘deuterium switch’ approach, such as deutetrabenazine, which became the first deuterated drug to receive FDA approval in 2017. In the past few years, the focus has shifted to applying deuteration in novel drug discovery, and the FDA approved the pioneering de novo deuterated drug deucravacitinib in 2022. In this Review, we highlight key milestones in the field of deuteration in drug discovery and development, emphasizing recent and instructive medicinal chemistry programmes and discussing the opportunities and hurdles for drug developers, as well as the questions that remain to be addressed.

From AI:

Deuterium, a stable isotope of hydrogen, is increasingly used in medicine to improve drug properties, particularly pharmacokinetics and toxicity profiles. Deuterated drugs are created by replacing hydrogen atoms with deuterium in a drug molecule, potentially slowing metabolism, increasing half-life, and reducing the production of toxic metabolites. This approach can lead to improved efficacy, safety, and tolerability.
Elaboration:
Deuterated Drugs:
These are medications where hydrogen atoms in the drug molecule are replaced with deuterium.
Benefits of Deuteration:
Improved Pharmacokinetics: Deuteration can slow down drug metabolism, leading to longer half-lives and potentially reducing the need for frequent dosing.
Reduced Toxicity: By altering metabolic pathways, deuteration can decrease the formation of toxic metabolites.
Enhanced Selectivity: It can help reduce the formation of non-selective metabolites, improving the drug's target selectivity.
Increased Bioavailability: In some cases, deuteration can enhance the oral absorption of drugs.
Examples:
Deutetrabenazine (Austedo): The first FDA-approved deuterated drug, used for Huntington's disease.
Deucravacitinib: Approved for treating autoimmune diseases like Sjögren's syndrome, rheumatoid arthritis, and psoriasis.
Mechanism:
The kinetic isotope effect (deuterium has a slightly larger mass than hydrogen) can influence the rate of reactions, including those involving metabolic enzymes.
Application:
Deuterium is used in various stages of drug discovery and development, including:
Designing new lead compounds.
Improving the properties of existing drugs.
Understanding drug metabolism.
Challenges:
While promising, the use of deuterium in drug development also faces challenges, including the need for further research and understanding of the impact of deuteration on various drug properties.

I was using Google AI which didn't come up with this. Or perhaps I used the wrong word order? But I still hadn't found any published research papers on Ampalex-d10. I wonder what source your AI found?
And why haven't we heard of this before from RSPI? Truly incredible!

AI Overview

Yes, RSPI (RespireRx Pharmaceuticals Inc.) and Ampalex-d10 are related, as Ampalex-d10 is a deuterated analog of Ampalex, a compound that was initially developed by Cortex Pharmaceuticals, a company that later became RespireRx Pharmaceuticals.
Here's a breakdown of the connection:
1. RespireRx Pharmaceuticals (RSPI):
RSPI is a biopharmaceutical company focused on developing therapies for neurological and respiratory disorders.
They have a drug platform called EndeavourRx, which includes the AMPAkines program.
2. Ampakines and Ampalex:
Ampakines are a class of drugs that act as positive allosteric modulators (PAMs) of AMPA receptors.
Ampalex (CX-516) was the first ampakine developed by Cortex Pharmaceuticals (now RespireRx).
3. Ampalex-d10:
Ampalex-d10 is a deuterated version of Ampalex.
Deuteration involves replacing hydrogen atoms with deuterium, which can enhance metabolic stability and allow for better tracking in pharmacokinetic studies.
In Summary:
Ampalex-d10 is a research tool derived from Ampalex, which was originally developed by the company that eventually became RespireRx Pharmaceuticals. Therefore, RSPI and Ampalex-d10 are connected through their shared history and the ongoing development of AMPAkine-based therapies.

https://en.wikipedia.org/wiki/CX-516 , then click on the highlighted blue names , cares to more info . Going to dig into it alittle more will post if I find anything GLTA

bigtalan - "...plays a crucial role in neuropharmacology." Has anyone seen papers on this compound? If true, development likely occurred before the patent for CX516 expired. Also, "crucial role" just what is its activity? Are other RSPI compounds "enhanced" with deuterium?

Ampalex-d10 is a compound developed and produced by Toronto Research Chemicals (TRC), a global provider of specialized chemicals. It is specifically a deuterated small molecule compound, meaning it's been labeled with deuterium, a stable isotope of hydrogen. TRC supplies the compound in 10 mg quantities.

https://www.pharmaffiliates.com/en/1286653-21-1-ampalex-d10-pasti007630.html

https://www.biosynth.com/Files/Gen/Tse/LBC65321

"Ampalex-d10 is a pharmaceutical compound that plays a crucial role in neuropharmacology. It is a derivative of Ampalex, with the incorporation of deuterium atoms, which significantly alters its physical and chemical properties." Ampalex is a commercial name for CX516 which came about in Cortex days. This is the first time I came across Ampalex-d10 so this compound could either be quite new or by the above statement it has been in secret preclinical trials. Does RSPI own its rights? Are there secret preclinical trials conducted by RSPI we don't know about? I have never heard of any organic compound where the hydrogens and replaced by deuterium and it changes its biochemical activity???

The implications are mind boggling.

Yes. Respire has multiple avenues for potential success and significant valuation reset compared with this peanuts valuation it has be stricken with since the inception of going quiet on the EM and really well before that as well. As some have stated though, it gave some of us the opportunity to acquire dirt cheap postions a year or two ago...

Obviously, with KRM-ll-81 advancing towards clinical trials along two potential lucrative pathways... Pain and Epilepsy, this is the bell cow and positioned to see one of those amazing pharma stock runs as it emerges into funding/partnerships/clinical trials...

Not to discount the potential in the ampakine CX-1739. My interpretation of their commentary is they would love to see that phase 2 SCI kick off with DOD funding and move it towards ADHD trials which is a much more lucrative market. That has to be their #1 objective for ampakines before exploring anything else in that space as there is a history to overcome with ampakines in general from my readings. The OSA program holds significant potential as well, but it is unclear why that is completely stalled.

I think this just adds to the consternation of the situation on the EM. Not only does it derail confidence in the leadership here, but all the secondary assets and possibilities appear stalled as well, eroding value. Hopefully, indeed they are preparing to emerge with a strategy soon and funding whether venture or BP cash to not only get the bell cow into clinics but prepare and move the ball forward on the other platforms as well. Fast and Furious corrections happen in pharma all the time. GLTA.

LT - Granted. But I fell we must also consider, when evaluating a company, its potential for future growth. There is no doubt (at least in my mind) that RSPI has enormous potential above what it currently has. That potential will add to the value of RSPI when it starts to trade again. I suspect it will be on the NASDQ, but we will see.

AI came up with the possible ampakine use in diabetes 2, I could find no literature on this application. Are the RSPI folks even aware of this potential? Is AI a better predictor for a research path than Bayesian statistics?

The focus is on KRM-ll-81. The selectivity profile appears to be best-in-class to address pain. Just listen to the CSO/CEO's words as well at the science team in publications about it. The competitor gabakines and their actions point towards this selectivity profile for pain. With also showing success for treatment resistent epilepsy, this science team probably could direct a significant program towards clinical trials in epilepsy as well. Hopefully the grant funding is secured to move on that medical indication as well.

Make no mistake, these efforts are significant with potential transformative impacts for the company and the improvement of medication for these medical indications. It is a no brainer for venture capital or BP to be locking in on this opportunity. Hopefully the "all aboard" call is coming out and this train is ready to leave the station. GLTA.

Nah, I think anything other than getting CX-1739 initiated in SCI phase 2 and ADHD phase 2 trials is the only path to "sudden" generation of value. Any and all other amapkines appear to be at square one in need of funding to re-discover and re-start at the preclinical/discovery phase. Most of the publication effort and academia work is based on old technology, not as viable for clinical development, patent expiration, etc.

If I am right about the extraordinary potential of ampakines, and it turns out to be true, a number of us will suddenly become quite wealthy. "Thar's gold in them thar hills!" remains to be seen.

Diabetes Metab Syndr Obes
. 2014 Jun 24;7:241–253. doi: 10.2147/DMSO.S43731
AMPK activation: a therapeutic target for type 2 diabetes?*

• Cited 552 times

The query "AMPK ampakine CX" suggests a focus on compounds that are both ampakines (positive allosteric modulators of AMPA receptors) and may also have an impact on AMPK (AMP-activated protein kinase). Several compounds like CX-717 and CX-516 (Ampalex) fit this description.
Key Points:
• AMPK:
AMPK is a protein kinase that plays a crucial role in energy metabolism and cellular signaling.
• Ampakines:
These are drugs that enhance the activity of AMPA receptors, which are ion channels that mediate excitatory neurotransmission in the brain.
• CX-717:
This compound is an ampakine that has shown antidepressant-like effects and can increase brain-derived neurotrophic factor (BDNF).
• CX-516 (Ampalex):
This compound is also an ampakine used in research on Alzheimer's disease, schizophrenia, and mild cognitive impairment.
• Potential Interactions:
Ampakines like CX-717 and CX-516 may influence AMPK activity, as AMPK is involved in various cellular processes that are also modulated by AMPA receptor activation.

Can an ampakine have a role in curing diabetes 2 ?

AI answers:
While an "ampakine" (AMP-activated protein kinase) does not cure type 2 diabetes, it can play a significant role in managing and potentially improving the condition. AMPK activation can enhance insulin sensitivity, reduce glucose production, and improve overall metabolic health.

One thing that will be interesting is their approach to IND/phase 1 clinicals for pain coming out of NIH HEAL program.

Will they look to obtain some funding and handle some initial phase 1 trials on their own?
Or given how similar gabakines have done well in phase 1, will BP make the leap now and partner up with upfront cash and milestones?

And will they simultanteuosly be conducting IND enabling studies or plan an IND submission for treatment resistent epilepsy.

And that is just one platform, the other two show promise as well if they can just get them kickstarted...

GLTA.

If you go back and read all their press, commentary and activities for the past say 4 years the themes boil down quite simply.

KRM-ll-81 is progressing within the HEAL program for non-opioid pain management. Tier 3 status is implementation phase leading to IND submission and phase 1 clinical trials. NIH timelines would suggest this is getting closer. This would be absolutely huge.

KRM-ll-81 is also mentioned continuously to be potential solution for treatment resistent epilepsy. This is mentioned to be the focus of the grant funding with the consultant group. Again, NIH timelines suggest they should already know or very soon the status of getting funded. Logic would suggest this would be IND enabling as well to lead to IND submission.

CX-1739 obviously awaiting traction to tap the DOD phase 2 funding for SCI. While they mention CX-717 ready for phase 2 ADHD, my notes suggest CX-1739 would be far superior and I would be curious if that isn't the source of SBIR funding for ampakine program they mention they would like to apply for.

OSA program: Stalled for unknown reasons.

All 4 of these key development paths have significant potential and are more reflective of a thorough approach by mid-major pharmas. What in the world they are doing on this EM with poor communication and presentation is dissappointing on so many levels. Clearly they are waiting for something. Once they take a more professional approach to the investment community, I would speculate a cascade of information and activities will ensue.

Hard to imagine at least 1 out of 7(?) Candidates not making a big splash, as a minimal expectation for RSPI in the next 12 minths?

RespireRx Pharmaceuticals Inc.'s (RSPI) potential for success

AI: Based on its pipeline, consider these key aspects:

1. RSPI's Pipeline and Target Areas:
RespireRx focuses on developing treatments for neurological and psychiatric disorders.
They have two main drug platforms:
ResolutionRx: Pharmaceutical cannabinoids, including dronabinol, targeting conditions like chemotherapy-induced nausea, anorexia in AIDS patients, and obstructive sleep apnea (OSA).
EndeavourRx: Neuromodulators, including:
AMPAkines: Positive allosteric modulators of glutamate receptors, potentially for CNS disorders, spinal cord injury, and orphan diseases.
GABAkines: Positive allosteric modulators of GABAA receptors, potentially for epilepsy and pain.
Specifically, they're developing treatments for conditions like epilepsy, pain, ADHD, spinal cord injury recovery, certain orphan diseases, and OSA.
2. Potential for Success:
Addressing Unmet Needs: RespireRx targets areas with limited or poor treatment options, which could be a significant advantage if their drugs prove effective and safe.
Novel Drug Platforms: They utilize proprietary compounds and target specific receptors, potentially leading to unique efficacy profiles and reduced side effects, giving them a competitive edge.
Advancing Clinical Trials: They've received a Department of Defense award to fund a Phase 2 clinical study for CX1739 (an AMPAkine) to improve bladder function in spinal cord injury patients, indicating progress in their pipeline.
Collaboration & Grants: Their collaboration with Shirley Ryan AbilityLab and receipt of the DOD grant suggests a proactive approach to research and development, which can be a positive sign for future success.
3. Challenges and Considerations:
Clinical Trial Success: The success of any pharmaceutical company hinges on the outcome of clinical trials. Even promising drugs can fail at this stage.
Regulatory Approvals: Obtaining regulatory approval can be a lengthy and costly process.
Funding & Resources: Developing and commercializing drugs requires substantial financial resources, which can be a challenge for smaller companies.
Competition: The pharmaceutical industry is competitive, and RespireRx will need to differentiate itself to succeed.
Market Adoption: Even with approvals, market acceptance and adoption of their products will be critical to commercial success.
In Conclusion:
RespireRx's pipeline shows promise, targeting areas with high unmet medical needs. Their focus on novel drug platforms and recent progress in clinical trials are encouraging signs. However, like all pharmaceutical companies, they face significant challenges related to clinical trial success, regulatory approvals, funding, and market competition. The potential for a successful company depends on their ability to navigate these challenges and bring their drugs to market effectively.

Thing is they already spun out the OSA formulation to ResolutionRX. And I believe the intent was to have that entity trading somewhere at some point in time. It hasn't done anything since 2023, so even with funds committed, there must be a significant hurdle remaining. Maybe USA regulations with cannibas/cannibas derived, but that is just speculation since the company is silent about everything.

I would guess considering the history of the ampakine platform, they need to prove a lot before they get significant investment beyond this DOD funding which they can't even get going for some reason. Maybe some SBIR funds will come in for another indication like ADHD, maybe they can take some cash from say any gabakine platform deal and make progress. But if you were a major investor you wouldn't want the ampakine and gabakine platforms intertangled... At least I would not.

So would they reverse merge everything? Or sell off the other two platforms? In the shareholder letter they talked about individual asset valuation, funding the LLC, etc, etc... Is the OTC trading venue a place for a company with a prime asset that may garner upfront cash and huge milestone payments in the months and years to come? Seems like there would be a ton of logic to find a way onto the NASDAQ with the gabakine asset.

They have to do something sooner or later. Material events need to be disclosed and if they are approaching IND submission or funding or BP/partnership news, they better have a strategy to freaking communicate and have the company trading on a liquid platform.

AI output concerning LBF Dronabinol. Another multi-billion dollar platform for RSPI?

The acronym "LBF" in the context of Dronabinol likely refers to Lipid-Based Formulations.
Here's why and what that implies:
1. What are Lipid-Based Formulations (LBFs)?
LBFs are drug delivery systems that utilize lipids (fats) and oils to improve the absorption and bioavailability of poorly water-soluble drugs, which is a common characteristic of many pharmaceutical compounds.
They can take various forms, such as self-emulsifying drug delivery systems (SEDDS), liposomes, and microemulsions.
2. Why Use LBFs for Dronabinol?
Dronabinol, a synthetic form of THC, is known to have low oral bioavailability due to its poor water solubility and extensive first-pass metabolism.
LBFs can help to improve the absorption of dronabinol by enhancing its solubility in the gastrointestinal tract and protecting it from degradation.
They may also help to reduce the food effect on dronabinol absorption, meaning that the drug's effectiveness is less dependent on whether it is taken with or without food.
3. LBFs and Dronabinol:
Research has explored the use of LBFs to deliver dronabinol, including the comparison of a dronabinol oral solution (Syndros) with dronabinol capsules (Marinol), where the solution may be considered a type of LBF.
Studies have investigated how LBFs can help overcome the food effect on dronabinol's pharmacokinetics, which can vary with different formulations and food intake.
In general, LBFs are considered promising strategies for improving the delivery of poorly water-soluble drugs like dronabinol.
In summary: "LBF" Dronabinol suggests a formulation of the drug designed to improve its absorption and bioavailability, potentially reducing variability and increasing its effectiveness, by utilizing a lipid-based drug delivery system.

RSPI, I like to see them file and get back on the OTC, followed by a reverse Merger*

WHO KNOWS ??

"A Patient man Never Waits"

RSPI THE GOLDEN TICKET, FOR LONGS $$$$$$$

"Regardless of what market this will go on in the future the potential is fantastic"

Yes. I would speculate the intent of the EndeavourRx LLC is to place KRM-ll-81 or the entirety of the gabakine program into that entity. Allow Institutional/BP to take some equity ownership and maybe eventually spin that out to NASDAQ via M&A or such. I am speculating that this talk about "in-licensing" additional candidates would more than likely be related to epilepsy as it makes the most sense as the other platforms are slow developing for that consideration. Of course as Neutrino mentioned, maybe anxiety becomes a prominent indication for this program as well. Who knows. But their gabakine program could be premier and carry significant valuation on a better exchange.

Bottomline is everything is waiting on them to emerge with a strategy from this EM. Maybe they don't intend to go back to the OTC and find a way now to a better exchange. Seems if you wanted to trade minor shares and fund a bit with dilution they could have went alternative reporting long ago...

I agree, even if there are a few brokers who now quote it and some are able to acquire positions in the U.S. there will not be any meaningful liquidity.

They need to address the SEC filings, simple as that.

"So regardless whether Respire finally relays a strategy to update filings and get off the EM, it looks like this becomes a quotable and thus slightly more liquid entity come July 1st."
That's not the import of this statement:
"Issuers that do not provide updated information, ongoing reporting and the required management certifications will see their securities transition to the Pink Limited Market or to the Expert Restricted Market, whichever is applicable. This will make it clear that the issuer has no ongoing relationship with OTC Markets Group, while still allowing broker-dealers to serve clients willing to trade these securities."

Broker-dealers can trade Expert Market securities NOW, they just can't quote them and they just choose not to take on any new positions. Nothing will change regarding RSPI trading in July unless they address their filing failure.

.0008 x .0018

And any high potential drug candidate/partnership to address the pain market, institutional would want a piece to support and add in their portfolios...

One of the other thoughts floated around is considering this extensive time frame being on the EM, if a reverse merger is a possibility. Would be some logic behind that to find maybe a Nasdaq listed pharma with some cash but failed assets. The progress and potential in their gabakine program and their ambitious shareholder letter would be positioned very well to do so.

Also interesting around the time of the shareholder letter, there was multiple investor conferences and that attempt at a website of information.... Not a peep in over 3 months about all that.

Have they locked in some funding where they no longer need to attend events or update that makeshift website?